PEAK6 Investments’s Relmada Therapeutics RLMD Stock Holding History

PEAK6 Investments’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-962	Closed	-$36K	–	5093
2022 Q3	$36K	Buy	+962	New	+$26.7K	﹤0.01%	4417

Other funds holding RLMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PEAK6 Investments's RLMD Position: Q4 2022 in Review

PEAK6 Investments sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 962 shares — an estimated $36K sold.

PEAK6 Investments first reported a position in RLMD in Q3 2022 and held it in 1 quarter. The position peaked at $36K in Q3 2022. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

PEAK6 Investments reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
PEAK6 Investments sold 962 Relmada Therapeutics shares in Q4 2022, an estimated $36K.
PEAK6 Investments first reported a position in Relmada Therapeutics in Q3 2022 and held it in 1 quarter.
PEAK6 Investments's Relmada Therapeutics position peaked at $36K in Q3 2022.
110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on PEAK6 Investments's 13F filing for Q4 2022, filed 10 Feb 2023.